AlzBiomarker
Control vs Alzheimer's Disease: tau-p181 (CSF)
A large number of studies over the past 20 years have quantified phosphorylated tau protein in the cerebrospinal fluid of people with Alzheimer’s disease, with the majority of assays using antibodies targeting tau phosphorylated at threonine 181 (tau-p181). Meta-analysis showed that the level of tau-p181 in the CSF of control subjects is about half that of people with AD (effect size = 0.530, p <0.0001).